

**Product Name**

Monoclonal Human anti-Four and a half LIM domains protein 1 Immunoglobulin

**CAT No.**

MQR 2.3201

**LOT No.**

18293

**Quantity**

100 µg

Edition: September 11, 2019

**Intended use**

This product is for research use only. NOT for use in diagnostic or therapeutic procedures.

This product is tested for use in enzyme-linked immunosorbent assay (ELISA) and immunoprecipitation (IP).

**Reagent provided**

The antibody is supplied in PBS.

**Isotype**

Human IgG1k

**Immunogen**

Four and a half LIM domains protein 1.  
Domain: A2-L280 of 280, bromodomain 1.

**Specificity**

Specificity has been tested in ELISA (figure 1) and IP-MS.

**Purity**

Protein A purified.

**Disclaimer**

The antibody is for R&D use only. NOT for use in diagnostic or therapeutic procedures.

**Precautions**

1. For professional users.
2. As with any product derived from biological sources, proper handling procedures should be used.
3. The product may be used in different techniques and in combination with different sample types and materials, therefore each individual laboratory should validate the applied test system.

**Preparation of the antibody**

Use antibody as supplied.

**Storage/Stability**

Store at -20°C. After first time use, store at 4°C. Avoid repeated freeze-thaw cycles.

**Application guidelines**

ELISA: 1:200 – 1:1000

IP: 2 µg/ml

Other applications: since applications vary, optimum working dilution of the product should be determined in the appropriate assay.

Unless the stability in the actual test system has been established, it is recommended to dilute the product immediately before use.

**Relevance**

Four and a half LIM domains protein 1, Mutations in the gene encoding this protein are the causative factor of several X-linked hereditary myopathies that are collectively termed FHL1-related myopathies. These disorders are characterized by severe muscle dysfunction and damage. It has also been shown that patients with idiopathic inflammatory myopathies (IIMs, Myositis) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25% of Myositis patients.




Figure 1: Specificity of anti-FHL1 (MQR2.3201), determined by ELISA. Antibody stock 0.35 mg/ml diluted in PBS containing 0.05% tween-20 and 1% BSA was tested on human Four and a half LIM domains protein 1 (in blue) and non-target protein (in red)..

**References**

- 1) <https://www.uniprot.org/uniprot/Q13642>